In addition to the previously noted studies demonstrating involvement of host immunity in therapeutic response, our own studies with murine EML4-ALK-driven (19) and EGFR-mutant (20) lung cancer cell lines demonstrate a contribution of adaptive immunity to durable responses to the ALK inhibitor, alectinib and the EGFR inhibitor, osimertinib, respectively. Here, EML4 is linked to lung carcinoma.